Markets

Johnson & Johnson Announces Three-Year Data From Its Phase 3 GALAXI 2, 3 Trials Of TREMFYA Demonstrate Efficacy, Consistent Profile To Treat Crohn's Disease

Oct 12, 2026 · 04:12 PM ET· updated 1h ago

Johnson & Johnson (NYSE: JNJ) today announced new three-year data from the Phase 3 GALAXI 2 and 3 studies showing durable efficacy and a consistent safety profile for TREMFYA® (guselkumab) in adults with moderately

Why It Matters

Johnson & Johnson showed that their Crohn's medicine worked well for three years. When a company proves a medicine stays safe and works long term, it builds trust with doctors.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

JNJ264.50

+3.06 (+1.17%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.